ONO PHARMACEUTICAL CO.,LTD.

小野薬品工業株式会社 (securities code 4528; filing date 2026-06-15) is developing into a global specialty pharmaceutical company centered on its pharmaceutical business. The Group conducts pharmaceutical research and development, manufacturing, and sales as an integrated operation. As of 31 March 2026, it consisted of the Company and 28 subsidiaries and operated as a single pharmaceutical business segment. Its main growth strategies are “Maximizing Product Value—from a Patient-Centered Perspective,” “Strengthening the Pipeline,” “Expanding and Accelerating Global Operations,” and “Expanding Business Domains.” The Group is accelerating its global expansion and pursuing medium- to long-term growth through corporate transformation enabled by digital and IT capabilities, as well as by enhancing its human capital. Since fiscal 2023, the acquisition of Deciphera has strengthened its global development capabilities and expanded its sales platform in the US and Europe. Its product portfolio in Japan and overseas is expanding across oncology, immunology and inflammation, neurology, and other areas, with multiple core products including Opdivo intravenous infusion. In terms of its business segment structure, the pharmaceutical business is the sole segment, while Group companies undertake a range of activities including clinical development, manufacturing and sales, in-licensing and out-licensing, and investment activities.